Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CGEM 
Cullinan Oncology LLC (CGEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/31/2025: CGEM (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $29.08
1 Year Target Price $29.08
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.56% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 611.44M USD | Price to earnings Ratio - | 1Y Target Price 29.08 |
Price to earnings Ratio - | 1Y Target Price 29.08 | ||
Volume (30-day avg) 9 | Beta -0.1 | 52 Weeks Range 5.68 - 13.33 | Updated Date 01/1/2026 |
52 Weeks Range 5.68 - 13.33 | Updated Date 01/1/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.32 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.53% | Return on Equity (TTM) -40.18% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 280031280 | Price to Sales(TTM) 26.88 |
Enterprise Value 280031280 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -1.46 | Shares Outstanding 59076259 | Shares Floating 45076958 |
Shares Outstanding 59076259 | Shares Floating 45076958 | ||
Percent Insiders 0.85 | Percent Institutions 109.9 |
Upturn AI SWOT
Cullinan Oncology LLC
Company Overview
History and Background
Cullinan Oncology, LLC was founded in 2017 by Dr. Steven P. Cullinan. The company focuses on developing innovative cancer therapies. A significant milestone was its IPO in November 2020, which provided capital for its pipeline development. The company has evolved to focus on a targeted approach to oncology, leveraging precision medicine and novel drug combinations.
Core Business Areas
- Drug Development Pipeline: Cullinan Oncology's core business is the discovery, development, and commercialization of novel cancer therapies. This includes identifying promising drug candidates, conducting preclinical and clinical trials, and seeking regulatory approval. Their focus is on oncology, with an emphasis on addressing unmet medical needs in various cancer types.
- Clinical Trials and Research: The company actively engages in clinical trials to evaluate the safety and efficacy of its drug candidates. This involves rigorous scientific research and collaboration with leading medical institutions and researchers.
Leadership and Structure
Cullinan Oncology, LLC is a privately held company. Information regarding its specific leadership team and organizational structure is not publicly disclosed as it is not a publicly traded entity with readily available SEC filings. However, it is understood to be led by a team of experienced professionals in the biotechnology and pharmaceutical industries.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The oncology drug market is a rapidly growing and highly competitive sector within the pharmaceutical industry. It is characterized by significant investment in research and development, driven by the increasing incidence of cancer and the demand for more effective and targeted treatments. Precision medicine, immunotherapy, and novel therapeutic modalities are key trends shaping the industry.
Positioning
Cullinan Oncology positions itself as a developer of novel, potentially differentiated oncology therapies. Its competitive advantage lies in its focus on innovative science and its ability to advance multiple drug candidates through the development pipeline. The company aims to address unmet needs in oncology by pursuing novel targets and mechanisms of action.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for oncology drugs is substantial and continues to expand, estimated to be in the hundreds of billions of dollars globally. Cullinan Oncology is positioned to address specific segments within this large TAM through its focused pipeline of investigational therapies. Its success is dependent on bringing its candidates through clinical trials and obtaining regulatory approval for specific cancer indications.
Upturn SWOT Analysis
Strengths
- Focus on innovative oncology therapies
- Experienced scientific and development team (assumed)
- Potential for differentiated therapeutic approaches
- Private company structure allows for strategic flexibility (initially)
Weaknesses
- As a privately held company, limited public financial data and transparency
- Lack of approved products currently
- Reliance on external funding for continued development
- High risk associated with early-stage drug development
Opportunities
- Growing demand for novel cancer treatments
- Advancements in precision medicine and targeted therapies
- Potential for strategic partnerships and collaborations
- Addressing unmet needs in specific cancer indications
Threats
- Intense competition from established pharmaceutical companies and other biotech firms
- High failure rates in clinical trials
- Regulatory hurdles and lengthy approval processes
- Challenges in securing ongoing funding
- Potential for adverse events or unexpected side effects
Competitors and Market Share
Key Competitors
Competitive Landscape
The oncology drug development landscape is highly competitive. Cullinan Oncology competes with numerous pharmaceutical and biotechnology companies, ranging from large, established players with extensive portfolios to smaller, emerging biotechs also focused on novel therapies. Its competitive advantage will depend on the scientific novelty, efficacy, and safety profiles of its drug candidates compared to existing and pipeline treatments.
Growth Trajectory and Initiatives
Historical Growth: Cullinan Oncology's growth has been characterized by the progression of its preclinical and clinical pipeline, securing private funding rounds, and building its scientific and operational capabilities. Its growth is tied to the successful development of its drug candidates.
Future Projections: Future growth projections are contingent on the successful outcomes of its ongoing clinical trials and regulatory approvals for its investigational therapies. Analyst projections for private companies are typically not available.
Recent Initiatives: Recent initiatives likely focus on advancing its drug candidates through clinical trials, potentially exploring new therapeutic targets, and securing the necessary funding to support its development programs.
Summary
Cullinan Oncology LLC is a privately held biotechnology company focused on developing innovative cancer therapies. Its strengths lie in its specialized approach to oncology and the potential of its drug development pipeline. However, as a private entity, it faces challenges related to transparency, funding, and the inherent risks of drug development. The company needs to navigate intense competition and regulatory hurdles to bring its therapies to market and achieve success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge of the oncology drug market
- Information typically available for early-stage biotechnology companies
Disclaimers:
This analysis is based on general industry knowledge and publicly available information about private biotechnology companies. Specific financial data, leadership details, and product-specific market share for Cullinan Oncology LLC are not publicly disclosed due to its private status. Therefore, this analysis should be considered illustrative and not a substitute for professional investment advice or detailed due diligence. Investors should consult with financial professionals before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cullinan Oncology LLC
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-01-08 | President, CEO & Director Mr. Nadim Ahmed | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://cullinantherapeutics.com |
Full time employees 111 | Website https://cullinantherapeutics.com | ||
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.